IL13 and melanoma: In this context, the current study explored the efficacy of a novel targeted therapy consisting of the sequential administration of IL-13-functionalized long-circulating liposomes encapsulating SIM and EVs stabilized with PEG and loaded with doxorubicin (DOX) (Patras et al., 2021) on B16 melanoma.